ATE122238T1 - Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. - Google Patents
Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.Info
- Publication number
- ATE122238T1 ATE122238T1 AT88108793T AT88108793T ATE122238T1 AT E122238 T1 ATE122238 T1 AT E122238T1 AT 88108793 T AT88108793 T AT 88108793T AT 88108793 T AT88108793 T AT 88108793T AT E122238 T1 ATE122238 T1 AT E122238T1
- Authority
- AT
- Austria
- Prior art keywords
- component
- antibody
- lymphocyte
- bifunctional
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6020587A | 1987-06-10 | 1987-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE122238T1 true ATE122238T1 (de) | 1995-05-15 |
Family
ID=22028021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT88108793T ATE122238T1 (de) | 1987-06-10 | 1988-06-01 | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0294703B1 (de) |
AT (1) | ATE122238T1 (de) |
DE (1) | DE3853740T2 (de) |
ES (1) | ES2073394T3 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6121424A (en) * | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
WO1989006544A1 (en) * | 1988-01-15 | 1989-07-27 | Centocor, Inc. | Heteroligating antibodies and therapeutic uses thereof |
US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5173293A (en) * | 1989-02-23 | 1992-12-22 | Becton Dickinson And Company | Anti-T-cell antibodies as adjuvants |
US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
FR2649119A1 (fr) * | 1989-06-30 | 1991-01-04 | Centre Nat Rech Scient | Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels |
WO1991003493A1 (en) * | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
AU5670194A (en) * | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
UA40577C2 (uk) * | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
CA2312188C (en) | 1997-12-08 | 2010-06-29 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US6617135B1 (en) | 1999-08-09 | 2003-09-09 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
DK1252192T3 (da) | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
MXPA03008031A (es) | 2001-03-07 | 2003-12-04 | Merck Patent Gmbh | Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida. |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
DK1383785T3 (da) | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Rekombinant tumorspecifikt antistof og anvendelse deraf |
AU2002357784B2 (en) | 2001-12-04 | 2008-07-31 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
US7576186B2 (en) | 2002-04-23 | 2009-08-18 | Roger Williams Hospital | Compositions and methods for stem cell delivery |
EP1900753B1 (de) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür |
EP2267032A3 (de) | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür |
US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
JP4494977B2 (ja) | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質 |
CA2512545C (en) | 2003-01-10 | 2015-06-30 | Karen Silence | Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf) |
BRPI0418286A (pt) | 2003-12-30 | 2007-05-02 | Merck Patent Gmbh | proteìnas de fusão de il-7 |
EP1706428B1 (de) | 2004-01-22 | 2009-09-23 | MERCK PATENT GmbH | Antikrebs-antikörper mit reduzierter komplementfixierung |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
EP2949668B1 (de) | 2005-05-18 | 2019-08-14 | Ablynx N.V. | Verbesserte nanokörper-tm gegen tumornekrosefaktor alpha |
CA2608873C (en) | 2005-05-20 | 2017-04-25 | Ablynx Nv | Single domain vhh antibodies against von willebrand factor |
JP2009521912A (ja) | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低減された免疫原性を有する抗cd19抗体 |
ATE555125T1 (de) | 2005-12-30 | 2012-05-15 | Merck Patent Gmbh | Interleukin-12p40-varianten mit verbesserter stabilität |
AU2010238858A1 (en) | 2009-04-22 | 2011-12-08 | Merck Patent Gmbh | Antibody fusion proteins with modified FcRn binding sites |
EP2491056B1 (de) | 2009-10-22 | 2021-09-15 | Universiteit Twente | Vhh zur anwendung bei gewebereperatur, organregeneration, organaustausch und gewebekonstruktion |
JP6991979B2 (ja) | 2016-02-05 | 2022-03-04 | オリオニス バイオサイエンシズ ビーブイ | Cd8結合物質 |
US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
EP3749295A4 (de) | 2018-02-05 | 2022-04-27 | Orionis Biosciences, Inc. | Fibroblastenbindende wirkstoffe und verwendung davon |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8626412D0 (en) * | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
US4882424A (en) * | 1987-05-11 | 1989-11-21 | Dana-Farber Cancer Institute, Inc. | Activation antigen |
-
1988
- 1988-06-01 ES ES88108793T patent/ES2073394T3/es not_active Expired - Lifetime
- 1988-06-01 EP EP88108793A patent/EP0294703B1/de not_active Expired - Lifetime
- 1988-06-01 DE DE3853740T patent/DE3853740T2/de not_active Expired - Fee Related
- 1988-06-01 AT AT88108793T patent/ATE122238T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0294703A2 (de) | 1988-12-14 |
JPS643128A (en) | 1989-01-06 |
EP0294703B1 (de) | 1995-05-10 |
EP0294703A3 (en) | 1990-06-27 |
DE3853740T2 (de) | 1995-11-09 |
ES2073394T3 (es) | 1995-08-16 |
DE3853740D1 (de) | 1995-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE122238T1 (de) | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. | |
DE69033705D1 (de) | Hybride immunglobuline | |
DE69014474D1 (de) | Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente. | |
DE69028412D1 (de) | Verfahren zum transport von molekülen in eukaryotenzellen | |
DE3675440D1 (de) | Neue pfropfpolymerisate und deren abmischungen mit polyamiden. | |
ATE190724T1 (de) | Polymere phosphoniumsalze, die chemilumineszenzverstärkung von 1,2-dioxetanen hervorrufen, und deren verwendung. | |
PT85992A (de) | Verfahren zur bestimmung von anti-hiv, mittel dazu und ihre verwendung in diesem verfahren | |
DE3873843D1 (de) | Verfahren zum zusammenbau von batterien und geraet. | |
PT87809A (pt) | Promotoren zur expression von freemd-dna in methylotrophen bakterien deren gewinnung und deren verwendung | |
DE58904672D1 (de) | Verfahren zur herstellung einer festphasenmatrix. | |
DE3581185D1 (de) | Neue pfropfpolymerisate und deren abmischungen mit polyamiden. | |
ATE164381T1 (de) | Polyacrylamid-matrix-gel | |
TR23834A (tr) | Parafin bakimindan zengin petrollerde ve petrol fraksiyonlarinda(i) akis duezelticisi olarak atilik ve/ veya metakrilik asit esterlerinin seckin...... | |
DE59001699D1 (de) | Vorrichtung zum querschneiden und querschweissen von bahnen. | |
DE58906771D1 (de) | Neue Copolymere, deren Mischungen mit Poly(meth)acrylsäureestern und deren Verwendung zur Verbesserung der Fliessfähigkeit von Rohölen in der Kälte. | |
PT83994A (de) | Verfahren zur herstellung von pyridin-derivative und insektizide akarizide nematozide und molluskizide mittel | |
DE3852118D1 (de) | Protease-ähnliche zytotoxische lymphozyten-spezifische moleküle und verfahren. | |
ATE42640T1 (de) | Verfahren zum immobilisieren von substanzen an kunststoffestphasen und kunststoffestphasen zur verwendung in immunosorbentassays. | |
KR860008779A (ko) | 항체 형성 화합물의 제조방법 | |
DE3679072D1 (de) | Verfahren zum vorheizen von keramischen stoffen in verbindung mit deren anwendung in metallurgischen verfahren und vorrichtung zur durchfuehrung des verfahrens. | |
DE3863312D1 (de) | Herstellungsverfahren von methanol und in diesem verfahren zu verwendende katalysatorzusammenstellung. | |
ATE102249T1 (de) | Modulaerer zusammenbau von antikoerpergenen, dadurch hergestellte antikoerper und deren anwendung. | |
IT8522157A0 (it) | Dispositivo per anastomosi vascolari e simili con punti metallici. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |